US2008161286A1PendingUtilityA1
Beta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Est. expiryFeb 28, 2025(expired)· nominal 20-yr term from priority
A61P 9/04A61P 9/00A61P 9/06A61P 9/10B01J 21/04B01J 23/892B01J 23/622B01J 23/8926A61K 31/55C10G 45/34B01J 37/0213C07D 223/16B01J 23/626B01J 23/50B01J 37/0211B01J 23/62C07B 2200/13B01J 35/397
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A βd-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Claims
exact text as granted — not AI-modified1 . A βd-Crystalline form of ivabradine hydrochloride of formula (I):
2 . The βd-Crystalline form of ivabradine hydrochloride of claim 1 having a powder X-ray diffraction diagram exhibiting peaks at 9.2 and 13.6 deg 2 theta.
3 . The βd-Crystalline form of ivabradine hydrochloride of claim 1 having a powder X-ray diffraction diagram exhibiting peaks at 9.2, 12.5, 13.6, 17.3, 22.3 and 25.0 deg 2 theta.
4 . A pharmaceutical composition comprising as active ingredient the βd-crystalline form of ivabradine hydrochloride of claim 1 , in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers.
5 . A method for treating or preventing a condition requiring a bradycardic, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of the βd-crystalline form of ivabradine hydrochloride of claim 1 .
6 . A method for treating or preventing clinical situations of myocardial ischaemia and/or a condition involving rhythm disturbances, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of the βd-crystalline form of ivabradine hydrochloride of claim 1 .
7 . The method of claim 6 , wherein the clinical situation of myocardial ischaemia is selected from angina pectoris and myocardial infarct and associated rhythm disturbances.
8 . The method of claim 6 , wherein the condition involving rhythm disturbances is selected from supra ventricular rhythm disturbances and heart failure.Join the waitlist — get patent alerts
Track US2008161286A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.